Ma Shuren, Lin Yong Y, Tartell Lori, Turino Gerard M
James P. Mara Center for Lung Disease, St. Luke's-Roosevelt Hospital Center, 1000 Tenth Avenue, New York, NY 10019, USA.
Respir Res. 2009 Feb 25;10(1):12. doi: 10.1186/1465-9921-10-12.
Desmosine and Isodesmosine (D/I) are cross-linking amino acids which are present only in mature elastin. Changes in their concentration in body fluids indicate changes in elastin degradation and can be a reflection of tissue elastase activity. This study was undertaken to determine whether continuous therapy with the long-acting bronchodilator Tiotropium bromide (TTP) could result in reductions in D/I as measured by mass spectrometry in plasma, urine and sputum.
Twelve not currently smoking patients with chronic obstructive pulmonary disease (COPD), never on TTP, were selected for study. Levels of D/I, along with measurements of FVC, FEV1 and FEV1/FVC. were determined before starting TTP daily, and then one and two months after.
D/I decreased in plasma (10 of 12 patients), in sputum all (12 of 12), and in the percentage of free D/I in urine (10 of 12). Most patients showed slight increases in FVC and FEV1 percent predicted over two months.
The results are consistent with an effect of prolonged bronchodilitation by anti-cholinergic blockade to also result in reduced lung elastin degradation.
锁链素和异锁链素(D/I)是仅存在于成熟弹性蛋白中的交联氨基酸。它们在体液中的浓度变化表明弹性蛋白降解的变化,并且可以反映组织弹性蛋白酶活性。本研究旨在确定长效支气管扩张剂噻托溴铵(TTP)的持续治疗是否会导致血浆、尿液和痰液中通过质谱法测量的D/I降低。
选择12名目前不吸烟的慢性阻塞性肺疾病(COPD)患者,他们从未使用过TTP进行研究。在开始每日使用TTP之前,以及之后1个月和2个月时,测定D/I水平,同时测量用力肺活量(FVC)、第1秒用力呼气容积(FEV1)和FEV1/FVC。
血浆中D/I降低(12名患者中的10名),痰液中D/I均降低(12名患者中的12名),尿液中游离D/I百分比降低(12名患者中的10名)。大多数患者在两个月内预测FVC和FEV1百分比略有增加。
结果与抗胆碱能阻滞导致的长期支气管扩张作用也会降低肺弹性蛋白降解一致。